S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:MNOV

MediciNova Stock Forecast, Price & News

$5.43
+0.11 (+2.07 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.23
Now: $5.43
$5.43
50-Day Range
$5.32
MA: $5.94
$6.76
52-Week Range
$2.79
Now: $5.43
$13.25
Volume104,927 shs
Average Volume182,973 shs
Market Capitalization$264.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
MediciNova logo

Headlines

Form 8-K MEDICINOVA INC For: Jan 29 - StreetInsider.com
February 1, 2021 |  streetinsider.com
MNOV: $20M Investment to Fund Multiple Programs…
January 25, 2021 |  finance.yahoo.com
Form 8-K MEDICINOVA INC For: Jan 11 - StreetInsider.com
January 12, 2021 |  streetinsider.com
Otterbox Easy Grip Controller Shell - Yahoo Finance Australia
January 12, 2021 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500
Employees8
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Market Cap$264.34 million
Next Earnings Date4/22/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.24 out of 5 stars

Medical Sector

847th out of 1,972 stocks

Pharmaceutical Preparations Industry

405th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.43
+0.11 (+2.07 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MediciNova (NASDAQ:MNOV) Frequently Asked Questions

Is MediciNova a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MediciNova stock.
View analyst ratings for MediciNova
or view top-rated stocks.

What stocks does MarketBeat like better than MediciNova?

Wall Street analysts have given MediciNova a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediciNova wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MediciNova?

MediciNova saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 2,240,000 shares, a decrease of 17.6% from the January 28th total of 2,720,000 shares. Based on an average trading volume of 201,800 shares, the short-interest ratio is currently 11.1 days.
View MediciNova's Short Interest
.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for MediciNova
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) issued its earnings results on Thursday, February, 18th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.06).
View MediciNova's earnings history
.

How has MediciNova's stock price been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MNOV shares have increased by 65.0% and is now trading at $5.43.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MNOV?

1 equities research analysts have issued 1 year target prices for MediciNova's stock. Their forecasts range from $11.00 to $11.00. On average, they expect MediciNova's stock price to reach $11.00 in the next year. This suggests a possible upside of 102.6% from the stock's current price.
View analysts' price targets for MediciNova
or view top-rated stocks among Wall Street analysts.

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 71, Pay $803.37k)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer & Director (Age 55, Pay $588.57k)
  • Mr. Edward C. Stepanow Jr., CFO & Principal Financial Officer (Age 54)
  • Mr. John O'Neil CPA, Controller

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.81%), Northern Trust Corp (1.23%), Citigroup Inc. (0.94%), Bank of New York Mellon Corp (0.50%), Renaissance Technologies LLC (0.42%) and Nuveen Asset Management LLC (0.39%). Company insiders that own MediciNova stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends for MediciNova
.

Which institutional investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Nuveen Asset Management LLC, Alliancebernstein L.P., Renaissance Technologies LLC, and Jane Street Group LLC.
View insider buying and selling activity for MediciNova
or view top insider-selling stocks.

Which institutional investors are buying MediciNova stock?

MNOV stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., JPMorgan Chase & Co., Wells Fargo & Company MN, State of Wisconsin Investment Board, Prelude Capital Management LLC, Bank of New York Mellon Corp, and Virtu Financial LLC. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki.
View insider buying and selling activity for MediciNova
or or view top insider-buying stocks.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $5.43.

How much money does MediciNova make?

MediciNova has a market capitalization of $264.34 million.

How many employees does MediciNova have?

MediciNova employs 8 workers across the globe.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

Where are MediciNova's headquarters?

MediciNova is headquartered at 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.